Interferons News and Research

RSS

Scientists begin phase 2 clinical trials of lupus pill

Lupus is an autoimmune disease that attacks organs and can be fatal. There's no cure, so current treatments aim to limit damage and ameliorate symptoms.

22 Aug 2022

Research progress on the three-dimensional interaction between virus and host genome

A recent study reviewed the current progress on 3D interactions between host and viral genomes.

8 Aug 2022

The bat-virus relationship examined

A new study examines the role of bats as reservoirs of several viruses and the factors that contribute to the emergence of these viruses.

28 Jul 2022

Increased resistance to human interferons could be a potential driver of SARS-CoV-2 evolution

Researchers compared the potency of 17 human interferons (IFNs) against multiple SARS-CoV-2 variants.

27 Jul 2022

Scientists investigate how interferons interact with SARS-CoV-2 variants

Researchers at the University of Colorado Anschutz Medical Campus have investigated how antiviral proteins called interferons interact with SARS-CoV-2, the cause of COVID-19.

25 Jul 2022

Early treatment with interferons could mitigate severe COVID-19 in people with specific genetic factors

Researchers from the National Cancer Institute, part of the National Institutes of Health, and their collaborators have discovered that people of European and African ancestries who were hospitalized for COVID-19 are more likely to carry a particular combination of genetic variants in a gene known as OAS1 than patients with mild disease who were not hospitalized.

14 Jul 2022

The role of vitamin D in H1N1 influenza and SARS-CoV-2 infection

A new study focused on determining Vitamin D's role in SARS-CoV-2 and H1N1 influenza. In this study, researchers determined the effect of vitamin D supplements on the lung anti-viral response in animal models.

4 Jul 2022

How to develop an "all-variant" COVID vaccine

In a recent study published in Nature Immunology, researchers summarized their observations of humoral immune responses elicited in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infected people. Additionally, they discussed all the types of SARS-CoV-2 infection- and vaccine-induced neutralizing antibodies (nAbs).

30 Jun 2022

GPR183 gene a novel drug target for severe COVID-19

In a recent study posted to the bioRxiv* pre-print server, researchers provide the first preclinical evidence of the usefulness of antagonists of G-protein coupled receptor 183 (GPR183), also known as Epstein-Barr virus-induced gene 2 (EBI2), in reducing coronavirus disease 2019 (COVID-19) severity.

17 Jun 2022

Type I interferons play crucial role in fending off SARS-CoV-2

Researchers investigated whether individuals with breakthrough infections of COVID-19 pneumonia demonstrated normal antibody responses to vaccinations and whether they harbored type I interferon-neutralizing auto-antibodies.

16 Jun 2022

Scientists characterize type I IFN response during SARS-CoV-2 infection

In a recent study posted to the bioRxiv* preprint server, Canadian researchers assessed the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on interferon (IFN) response.

15 Jun 2022

Core body temperature increases host resistance to influenza virus and SARS-CoV-2 infection

A recent article posted to the Research Square* preprint server demonstrated that high body temperature elevates gut microbiota-reliant host resistance against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A viral infection.

10 Jun 2022

New compounds for cancer immunotherapy via STING-mediated immune activation

Innovations in cancer immunotherapy have achieved clinical success by considerably increasing the survival rate of patients undergoing cancer treatment.

31 May 2022

After SARS-CoV-2 infection, anti-chemokine antibodies correlate with better outcomes

A recent study posted to the bioRxiv* preprint server illustrated that specific chemokine antibodies aid in recognizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent individuals with a desirable disease course.

26 May 2022

Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study

A new paper presents the results of a mouse study using the repurposed antibacterial drug clofoctol against this virus.

23 May 2022

Study reveals how ZBP1 could lead to a cytokine storm during COVID-19

Scientists from St. Jude Children's Research Hospital have shown that the innate immune sensor, ZBP1, and its associated inflammatory cell death pathway, PANoptosis, are major contributors to the negative effects of interferon treatment and high interferon levels in some COVID-19 patients.

20 May 2022

COVID-19 mortality strongly predicted by autoimmunity to type I interferons and advancing age

In a recent study published in the journal PNAS, researchers estimated the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) and relative risk of death (RRD) among subjects across ages.

19 May 2022

Study shows why COPD patients are more vulnerable to severe COVID-19

Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe COVID-19.

18 May 2022

Camelid IFNs could play important role in combating emerging zoonotic pathogens

In a recent study published in the Developmental & Comparative Immunology journal, the discovery of a novel form of mammalian interferon-Beta (IFN-β) with four cysteine residues from the dromedary camel and the five remaining members of the mammalian suborder Tylopoda is described.

17 May 2022

Study reveals serum proteomic signatures of long COVID patients

In a recent study posted to the bioRxiv*preprint server, researchers evaluated the serum proteomic signatures of long coronavirus disease (COVID) patients.

13 May 2022